Evidence map›Paper›PMID 35320062›Full record

ArticleAmerican journal of respiratory and critical care medicine2022

Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.

Christoph Lange, Clifton E Barry, C Robert Horsburgh

Abstract readEditorialComment
In one paragraph

Article in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. New treatments for Drug Resistant TB: Past imperfect, future bright.Lung India : official organ of Indian Chest Society
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Christoph LangeDivision of Clinical Infectious Diseases Research Center Borstel Borstel, Germany.ORCID 0000-0002-9691-4741
Clifton E BarryNational Institute of Allergy and Infectious Disease National Institutes of Health Bethesda, Maryland.ORCID 0000-0002-2927-270X
C Robert HorsburghDepartment of Epidemiology Department of Biostatistics.ORCID 0000-0001-6838-7895

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment TrialU01AI152980 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Charles Robert Horsburgh, PAYAM NAHID · 2020 to 2026
$7.5M
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)R01AI134430 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HORSBURGH, CHARLES ROBERT, STERLING, TIMOTHY R · 2017 to 2021
$4.6M
Tuberculosis Research Institute at MUHASD43TW009573 · FIC · DARTMOUTH COLLEGE · PI ADAMS, LISA VIRGINIA · 2013 to 2022
$3.0M
Optimal targeting for individual and population-level TB preventionR01AI146555 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MENZIES, NICOLAS A · 2020 to 2024
$2.5M
FIC NIH HHS D43 TW009573NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI134430NIAID NIH HHS R01 AI146555NIAID NIH HHS U01 AI152980
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Tuberculosis, Multidrug-ResistantAntitubercular AgentsHumansAntitubercular Agents

Identifiers

PMID35320062
PMCPMC9872807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.